Abstract
Epidermolytic palmoplantar keratoderma (EPPK) is an autosomal dominant monogenic disease characterized clinically by symmetrical diffuse palmoplantar hyperkeratosis, and histologically by epidermolytic hyperkeratosis. Recent studies have demonstrated that keratin-9 (KRT9) and keratin-1 (KRT1) gene mutations are responsible for EPPK. In addition, environment and capecitabine may also contribute to its occurrence. At present, EPPK is mainly managed with symptomatic treatment. Small interfering RNAs (siRNAs) have gradually become a research hotspot, which may provide a basis for gene therapy of EPPK. With further insights into the molecular basis of this disease, its prenatal diagnosis has advanced continuously. Key words: Keratoderma, palmoplantar, epidermolytic; Epidemiology; Heredity; Autosomal dominant; Pathology, clinical
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Dermatology and Venereology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
